Antigen imitating extracellular areas of membrane proteins of type III produced from intracellular pathogenic micro-organisms, derived conformational antibodies and the use thereof

• US 7,803,378 B2
• Filed: 01/28/2004
• Issued: 09/28/2010
• Est. Priority Date: 01/28/2003
• Status: Expired due to Fees

• Current Assignee: Centre National De La Recherche Scientifique, Université de Liège, Universite de Rouen
• Original Assignee: Centre National De La Recherche Scientifique, Université de Liège, Universite de Rouen
• Inventors: Tranchand-Bunel, Denis
• Primary Examiner(s): Lucas; Zachariah
• Assistant Examiner(s): Boesen; Agnieszka
• Application Number:
  US10/544,081
• Publication Number:
  US 20080075717A1
• Time in Patent Office: 2,435 Days
• Field of Search: None
• US Class Current: 424/184.1
• CPC Class Codes: A61K 2039/525 Virus
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 16/085 Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C12N 2710/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/16622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

An antigen derived from an intracellular pathogenic micro-organism characterized in that it comprises at least on peptidic fragment which essentially consists of the concatenation of sequences of at least two extracellular adjacent areas in the native structure of a membrane protein of type III of said intracellular pathogenic micro-organism, derived conformational antibodies and the application hereof.

Claims

1. A chimeric antigen derived from Epstein-Barr virus (EBV), comprising an amino acid sequence selected from the group consisting of the sequences set forth in SEQ ID NO:

10, 11 and 13 to 23.

2. An immunogenic composition comprising an antigen combined with at least one pharmaceutically acceptable vehicle, wherein the antigen comprises an amino acid sequence selected from the group consisting of the sequences set forth in SEQ ID NO:

10, 11 and 13 to 23.